JP2022071099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022071099A5 JP2022071099A5 JP2022031616A JP2022031616A JP2022071099A5 JP 2022071099 A5 JP2022071099 A5 JP 2022071099A5 JP 2022031616 A JP2022031616 A JP 2022031616A JP 2022031616 A JP2022031616 A JP 2022031616A JP 2022071099 A5 JP2022071099 A5 JP 2022071099A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- flt3
- therapeutic agent
- genetic abnormalities
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 40
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 35
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 35
- 230000005856 abnormality Effects 0.000 claims 34
- 229940124597 therapeutic agent Drugs 0.000 claims 34
- 230000002068 genetic effect Effects 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 230000002062 proliferating effect Effects 0.000 claims 24
- 230000004083 survival effect Effects 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 15
- 208000032839 leukemia Diseases 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 11
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims 10
- 229950009240 crenolanib Drugs 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 108020003175 receptors Proteins 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 238000003205 genotyping method Methods 0.000 claims 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 5
- 208000034951 Genetic Translocation Diseases 0.000 claims 4
- 201000009928 Patau syndrome Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010044686 Trisomy 13 Diseases 0.000 claims 4
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims 4
- 206010053871 Trisomy 8 Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010837 poor prognosis Methods 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims 4
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims 3
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims 3
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims 3
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims 3
- 101150084041 WT1 gene Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000037437 driver mutation Effects 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 102100022678 Nucleophosmin Human genes 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 108700020467 WT1 Proteins 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 238000009093 first-line therapy Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 208000036878 aneuploidy Diseases 0.000 claims 1
- 231100001075 aneuploidy Toxicity 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- ARQUTWAXTHJROR-UHFFFAOYSA-N benzenesulfonic acid;1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Chemical compound OS(=O)(=O)C1=CC=CC=C1.C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 ARQUTWAXTHJROR-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 208000030454 monosomy Diseases 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064106A JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416475P | 2016-11-02 | 2016-11-02 | |
| US62/416,475 | 2016-11-02 | ||
| PCT/US2017/059377 WO2018085292A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
| JP2018506309A JP2019532011A (ja) | 2016-11-02 | 2017-10-31 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| US15/799,684 | 2017-10-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506309A Division JP2019532011A (ja) | 2016-11-02 | 2017-10-31 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064106A Division JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022071099A JP2022071099A (ja) | 2022-05-13 |
| JP2022071099A5 true JP2022071099A5 (enExample) | 2022-06-23 |
| JP7536320B2 JP7536320B2 (ja) | 2024-08-20 |
Family
ID=62020370
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506309A Pending JP2019532011A (ja) | 2016-11-02 | 2017-10-31 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2022031616A Active JP7536320B2 (ja) | 2016-11-02 | 2022-03-02 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2024064106A Withdrawn JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506309A Pending JP2019532011A (ja) | 2016-11-02 | 2017-10-31 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064106A Withdrawn JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11078541B2 (enExample) |
| EP (1) | EP3359155A4 (enExample) |
| JP (3) | JP2019532011A (enExample) |
| KR (2) | KR20200079351A (enExample) |
| CN (1) | CN108778276A (enExample) |
| AU (1) | AU2017353925A1 (enExample) |
| BR (1) | BR112019008762A2 (enExample) |
| CA (1) | CA3024012A1 (enExample) |
| CL (1) | CL2019001208A1 (enExample) |
| CO (1) | CO2019005466A2 (enExample) |
| EA (1) | EA201991078A1 (enExample) |
| HK (1) | HK1257195A1 (enExample) |
| IL (1) | IL266303A (enExample) |
| MX (1) | MX2019005008A (enExample) |
| PE (1) | PE20191238A1 (enExample) |
| PH (1) | PH12019500965A1 (enExample) |
| SG (1) | SG11201903889TA (enExample) |
| WO (1) | WO2018085292A1 (enExample) |
| ZA (1) | ZA201903089B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1257195A1 (zh) * | 2016-11-02 | 2019-10-18 | 安罗格制药有限责任公司 | 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| CN109678849A (zh) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | 一种抗癌药物的制备方法 |
| US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN110531016B (zh) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | 一种hyml-122血药浓度定量分析方法 |
| CA3186319A1 (en) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN112921091B (zh) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| JP2023063189A (ja) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| IL162203A0 (en) | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| RU2005106871A (ru) | 2002-08-14 | 2005-10-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы протеинкиназ и их применение |
| BR0313743A (pt) | 2002-08-23 | 2005-07-05 | Chiron Corp | Benzimidazol quinolinonas e usos destas |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| SG148864A1 (en) | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| CN100404530C (zh) | 2003-06-24 | 2008-07-23 | 辉瑞产品公司 | 1-[2-(苯并咪唑-1-基)喹啉-8-基]哌啶-4-基胺衍生物的制备方法 |
| EP3354753B1 (en) * | 2009-04-06 | 2020-02-12 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
| AU2013232379A1 (en) * | 2012-03-12 | 2014-09-25 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
| KR20140040594A (ko) | 2012-09-26 | 2014-04-03 | 아로그 파마슈티칼스, 엘엘씨 | 돌연변이체 c-kit의 억제 방법 |
| BR112015016282A2 (pt) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| HK1257195A1 (zh) * | 2016-11-02 | 2019-10-18 | 安罗格制药有限责任公司 | 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
-
2017
- 2017-10-31 HK HK18116172.6A patent/HK1257195A1/zh unknown
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/es unknown
- 2017-10-31 EA EA201991078A patent/EA201991078A1/ru unknown
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/ko not_active Ceased
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/ko not_active Ceased
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en not_active Ceased
- 2017-10-31 BR BR112019008762A patent/BR112019008762A2/pt not_active Application Discontinuation
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/es unknown
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/zh active Pending
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/ja active Pending
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/es unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/es unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US12404555B2/en active Active
-
2022
- 2022-03-02 JP JP2022031616A patent/JP7536320B2/ja active Active
-
2024
- 2024-04-11 JP JP2024064106A patent/JP2024096859A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,777 patent/US20250305063A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022071099A5 (enExample) | ||
| JP2019532011A5 (enExample) | ||
| Liu et al. | Small molecule inhibitors targeting the cancers | |
| JP7536320B2 (ja) | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ | |
| JP6288726B2 (ja) | 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ） | |
| CN115607552B (zh) | 取代的4-氨基异二氢吲哚-1,3-二酮化合物和第二种活性剂的组合用途 | |
| JP2014065696A5 (enExample) | ||
| JP7577672B2 (ja) | Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物 | |
| Chakraborty et al. | MAP-kinase-driven hematopoietic neoplasms: a decade of progress in the molecular age | |
| JP2021519262A (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| WO2019057141A1 (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| TW200908982A (en) | Treatment of imatinib resistant leukemia | |
| JP2023063189A5 (enExample) | ||
| WO2025033367A1 (ja) | 抗腫瘍剤併用療法 | |
| JP2013505939A (ja) | 組合せ | |
| US20250262216A1 (en) | Therapeutic uses of macrocyclic compounds | |
| WO2024249769A2 (en) | Combination therapy for treating hematological cancers | |
| CN110507675A (zh) | 包含藻蛋白多糖提取物的组合物及其用途 | |
| Higashi et al. | A Case of BRAF-V600E-Positive Pulmonary Pleomorphic Carcinoma Successfully Treated With Dabrafenib and Trametinib Administered via a Percutaneous Endoscopic Gastrojejunostomy Tube for Ileus Caused by Small Intestinal Metastasis | |
| CN120829970A (zh) | 一种肿瘤治疗用药辅助系统、药物组合物 | |
| JPWO2020068347A5 (enExample) | ||
| RU2846238C1 (ru) | Новое применение мультитаргетного ингибитора киназ | |
| Alshehri et al. | Personalized Medicine Approaches for Pediatric Leukemia: Developing Targeted Therapies Based on Genetic Profiles | |
| TWI813694B (zh) | 抗腫瘤劑及腫瘤治療方法 | |
| Adams et al. | Sequential Lineage Switch from B-ALL to AML to MPAL in an Elderly Patient with KMT2A/AFF1 Fusion |